🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise around the world, with data suggesting over 82 million new cases each year. Especially elevated rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in recent days for use against gonorrhoea. This infection can lead to significant complications, including infertility. Scientists anticipate that specific application of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in concurrent days. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone represents a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Outcomes and Worldwide Availability

Based on results detailed in a major medical journal, zoliflodacin eradicated over nine in ten of cases of the STI. This places it at an equal footing with the typical regimen, which combines an injection and a pill. The research involved over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the rights to make available and distribute the drug in many developing nations.

Doctors directly involved have voiced positive views. Having a one-pill regimen of this kind is described as a "critical tool" for public health efforts. This is viewed as vital to alleviate the strain of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea globally.